Zydus Presents Saroglitazar Analysis from EPICS-III Trial at ACG 2026

New Delhi: Zydus Therapeutics Inc., a wholly owned subsidiary of Zydus Lifesciences Ltd., has presented new exploratory analyses from the pivotal EPICS-III Phase 2(b)/3 clinical trial evaluating...
Read the full report on Business Medical Dialogues
Story file
- Section
- India
- Places
- Delhi
- First reported by
- Business Medical Dialogues
- Reporter
- sheeba farhat
- Published
- Sunday, 18 October 2026, 9:06 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Business Medical Dialogues with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.




